New data suggests the Cov19 FluoBolt-DAT detects antibodies against the new Omicron variant.
Quantitative Duplex Antibody Test (DAT) for antibodies to SARS-CoV-2
The Cov19 FluoBolt-DAT allows the simultaneous and quantitative measurement of antibodies against the S1 RBD AND Nucleocapsid antigen of SARS-CoV-2. In contrast, other antibody assays detect all antibodies generated against the S1- OR NC-protein. This test, however, is epitope specific. It detects immune-dominant antibodies species, i.e. the most important antibodies generated by either vaccination or infection.
This is demonstrated by the fact, that it detects anti-S1RBD against all dominant virus variants identified so far. The data indicates (see chart below) that the S1RBD part of the Cov19 FluoBolt-DAT assay detects the immune-dominant epitope and that individuals testing S1RBD -positive in the FluoBolt-DAT test have developed significant amounts of antibodies against this epitope. Therefore, they might be well protected against all current and future SARS-CoV-2 variants
